Surgeons face significant risks of iatrogenic ureteral injury during complex pelvic operations. Consequently, the adoption of nizaracianine ureteral imaging represents a major advancement in fluorescence-guided surgery. This near-infrared agent allows for real-time identification of anatomical structures. Furthermore, a recent Phase 1 study evaluated its safety and pharmacokinetics when administered in repeated doses. Researchers aimed to determine if divided dosing could sustain visualization during long procedures.

The trial included twenty-one healthy volunteers across four dose cohorts ranging from 0.5 to 5.0 mg. Participants received three divided doses at hourly intervals. Specifically, the team monitored vital signs, laboratory values, and electrocardiography to ensure participant safety. Notably, the study found that repeated intravenous doses were well tolerated. Although the researchers identified thirty-six adverse events, most related to catheter placement rather than the drug. Moreover, the pharmacokinetic analysis demonstrated clear dose proportionality for peak concentration and half-life.

Benefits of Nizaracianine Ureteral Imaging in Surgery

Consequently, fluorescence visualization appeared within just five minutes of administration. The signal persisted for up to eight hours after the initial dose. Therefore, this duration is particularly beneficial for prolonged abdominopelvic procedures. Additionally, cumulative renal clearance reached approximately 65%. This finding suggests that other non-renal pathways may also play a role in drug elimination. However, the consistent urine fluorescence confirms its utility for ureteral mapping without the need for invasive stenting.

In summary, nizaracianine provides a reliable safety profile for repeated administration. Therefore, it serves as a valuable tool for enhancing intraoperative visualization. Surgeons can now expect prolonged imaging windows without significant toxicity. Similarly, this advancement may reduce the incidence of accidental ureteral damage in clinical practice.

Frequently Asked Questions

How long does the fluorescence signal last after administration?

The study found that the fluorescence signal remains visible for up to eight hours after the initial dose, making it suitable for long surgeries.

Is repeated dosing of nizaracianine safe?

Yes, the Phase 1 trial demonstrated that three divided doses were well tolerated by healthy volunteers with no serious drug-related adverse events.

What is the primary clearance pathway for nizaracianine?

The drug is primarily renally cleared, with a cumulative renal clearance of 65% observed in humans, allowing for effective urine-based imaging.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Neijenhuis LKA et al. Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers. Br J Clin Pharmacol. 2026 Feb 08. doi: 10.1002/bcp.70459. PMID: 41656494.

Al-Taher M, et al. Fluorescence-guided surgery for ureteral identification: a systematic review. Frontiers in Oncology. 2021;11:654646.